Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)

February 25, 2013 1:15 PM EST Send to a Friend
Get Alerts ARNA Hot Sheet
Price: $4.08 -1.92%

Rating Summary:
    4 Buy, 9 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 28 | New: 24
Trade ARNA Now!
Join SI Premium – FREE
Arena Pharmaceutical (Nasdaq: ARNA) is positive on the session following earlier disclosure of the price for a 60-day supply of Belviq 10-mg tablets. The cost of $199.50 compares with VIVUS' (Nasdaq: VVUS) Qsymia, which retails for $160 per month at a medium dose and $220 per month for the higher dose.

Bloomberg Industries' Andrew Berens says the success of Belviq will largely depend on lower co-payments and broader insurance coverage.

One Leerink Analysts commented late last week that broad reimbursement may come to pass over the next two years, as treating obesity was seen as a better option by many versus treating co-morbidities. Competition might arise in identifying "correct patients" versus which therapy is better.

Arena is up 1.3 percent while VIVUS is 0.6 percent better on the session.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA, Trader Talk

Add Your Comment